MOMENTUMAZD3632 para malignidades hematológicas avanzadas con sobreexpresión de HOX

AZD3632

AZD3632

AZD3632

AZD3632

AZD3632

AZD3632

AZD3632

Posaconazole

Module 1: Number of participants with dose-limiting toxicity (DLT)

Module 1 and Module 2: Number of participants with dose modification, delay and discontinuations due to adverse events (AEs)

Module 1 and Module 2: Number of participants with treatment-emergent adverse events (TEAEs), treatment-related AEs (TRAEs) and serious adverse vents (SAEs)

Module 1 and Module 2: Maximum concentration (Cmax) of AZD3632

Module 1 and Module 2: Time of maximum concentration (Tmax) of AZD3632

Module 1: Trough concentration (Ctrough) of AZD3632

Module 1: Area under the plasma concentration-time Curve from Time Zero to Infinity (AUC[inf]) of AZD3632

Module 1 and Module 2: Area under the curve from time 0 to the time of last measurable concentration (AUC[0-t]) of AZD3632

Module 1: Area under concentration-time curve in the dosing interval (AUCtau) of AZD3632

Module 1: Apparent total body clearance (CL/F) of AZD3632

Module 1: Apparent volume of distribution based on the terminal phase (VZ/F) of AZD3632

Module 1: Half-life (t1/2) of AZD3632

Module 1: Maximum concentration (Cmax) of AZD3632 (food effect)

Module 1: Time of maximum concentration (Tmax) of AZD3632 (food effect)

Module 1 and Module 2: Area under the curve from time 0 to the time of last measurable concentration (AUC[0-t]) of AZD3632 (food effect)

Module 1: Area under concentration-time curve in the dosing interval (AUCtau) of AZD3632 (food effect)

Module 1: Minimum concentration (Cmin) of AZD3632 (food effect)

Module 1: Ratio of Cmax between fed and fasted state

Module 1: Ratio of AUC(0-t) between fed and fasted state

Module 1: Ratio of AUCtau between fed and fasted state

Module 2: Plasma geometric mean ratio of Cmax

Module 2: Plasma geometric mean ratio of AUC

Module 2: Plasma concentration of posaconazole

Module 1 and Module 2: Complete response rate (CR + CRh)

Module 1 and Module 2: Time to response (TTR)

Module 1 and Module 2: Duration of response (DoR)

Module 1 and Module 2: Transfusion Independence (TI)

Module 1 and Module 2: Event-free Survival (EFS)

Module 1 and Module 2: Overall Survival (OS)

Module 1 and Module 2: Percentage of participants who receive subsequent allogeneic hematopoietic stem cell transplant (HSCT)

Module 1 and Module 2: Overall Response Rate (ORR)

Module 1 and Module 2: Time to Progression to acute myeloid leukaemia (AML)